September 2014 | OncologyLive

Making the Molecular Leap

September 29, 2014

Our coverage of the 15th Annual International Lung Cancer Congress, which Physicians' Education Resource (PER) hosted July 31-August 2 in California, illustrates how nuanced genomic targeting has become in NSCLC.

Targeting Mitosis: First Polo-Like Kinase Inhibitor Moves Closer to FDA Approval

September 25, 2014

The concept of targeting mitotic cell division to halt the progression of rapidly dividing cancer cells has long been a staple of oncology therapy, yet chemotherapy agents that are the prime examples of this approach are nonselective in their action and can kill normal and malignant cells alike.

Changing Trends in Prostate Cancer Therapy: Is Earlier Better?

September 24, 2014

Although the incidence and mortality of prostate cancer remain formidable problems in the United States, clinicians have many new agents with proven overall survival (OS) benefits to recommend for patients with metastatic disease.

Screening for Distress Now a Routine Part of Quality Cancer Care-At Last

September 23, 2014

At the 2014 ASCO meeting, OncologyLive sat down with Jimmie C. Holland, MD, the Wayne E. Chapman Chair in Psychiatric Oncology at Memorial Sloan Kettering Cancer Center and the recipient of the 2014 Giants of Cancer Careâ„¢ Award for her pioneering contributions in the field of supportive care.

Most Breast Cancer Patients Forgo Reconstruction Surgery Without Regret

September 22, 2014

Although universal insurance coverage for postmastectomy breast reconstruction has been mandated since 1998, a new study has found that the persistently high rates of American women who choose not to undergo reconstruction surgery are due primarily to patient preferences and not a lack of awareness.

Molecular Era Tumor Boards: Team Approach to Interpreting Genomic Test Results Proves Valuable

September 11, 2014

How can a conscientious but very busy practitioner keep up with the massive quantity of molecular data that could potentially impact an individual patient with cancer? The Moores Cancer Center at the University of California, San Diego has updated the tumor board concept for the molecular era.